44 results about "Inhibitory cell" patented technology

A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.

The present invention relates to preventing or delaying programmed cell death by expressing one or more anti-apoptotic polypeptides in a cell such that programmed cell death in the cell is prevented or delayed. The present invention also relates to increasing production of a cell-related product by expressing one or more anti-apoptotic polypeptides in a cell such that production of the cell-related product by the cell is increased. Recombinant cells useful for producing cell-related product or cellular therapy are also provided.

In one aspect the present invention provides methods for inhibiting cell death or inflammation in a mammal, wherein the methods each include the step of administering to a mammal a Bcl protein in an amount sufficient to inhibit cell death or inflammation in the mammal. The invention also provides methods for identifying a Bcl protein that inhibits cell death or inflammation when administered to a mammal.

It is intended to provide a substance having an effect of shrinking pores by analyzing the mechanism of making pores perceptible and compositions such as a skin preparation for external use which exerts the above effect to thereby make pores imperceptible. As means for solving these problems, there are provided a parakeratosis inhibitor and a pore-shrinking agent comprising an antagonist to an excitatory cell receptor, for example, a glutamate receptor such as N-methyl-D-aspartic acid receptor or an ATP receptor such as P2X receptor, or an agonist to an inhibitory cell receptor such as a γ-aminobutyrate receptor such as bicuculline-sensitive receptor having the Cl-channel therein or glycine receptor, as well as a skin preparation for external use aiming at inhibiting parakeratosis and a skin preparation for external use aiming at shrinking pores each containing such an antagonist to an excitatory cell receptor or an agonist to an inhibitory cell receptor as described above. Owing to the effects of inhibiting parakeratosis and shrinking pores, the skin can be maintained in a healthy state without perceptible pores.

The invention discloses the application of the p53 gene to reversing of mouth mucosa malignant melanoma cell malignant characteristics, and an in vitro evaluation method for reversing of the mouth mucosa malignant melanoma cell malignant characteristics, and belongs to the technical field of cellular and molecular biology. According to the invention, a gene therapy method is applied to the reversing of mouth mucosa malignant melanoma cell malignant characteristics and the in vitro evaluation method for reversing of the mouth mucosa malignant melanoma cell malignant characteristics; by introducing the exogenous wild-type p53 gene into a malignant melanoma-related cell strain, using various mechanisms, and depending on synthetic action of various signal transduction pathways, cell growth is inhibited, meanwhile, the cell cycle distribution is changed, cells are induced for apoptosis, and the malignant characteristics of cell transfer and invasion can be reversed. The evaluation method is simple and reliable, is scientific and rational, is capable of comprehensively detecting the reversing condition of the mouth mucosa malignant melanoma cell malignant characteristics, and can be used not only for studying of oral mucosa malignant melanoma pathogenesis, but also for screening of related drugs for oral mucosa malignant melanoma.